JBC Oz Biosciences

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kafert, S.
Right arrow Articles by Eder, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kafert, S.
Right arrow Articles by Eder, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 46, 33064-33071, November 12, 1999


Functional Analysis of a Single Chain Chimeric alpha /beta -Granulocyte-Macrophage Colony-stimulating Factor Receptor
IMPORTANCE OF A GLUTAMATE RESIDUE IN THE TRANSMEMBRANE REGION*

Sabine Kafert, Susanne Luther, Inga Böll, Katharina Wagner, Arnold Ganser, and Matthias EderDagger

From the Department of Hematology and Oncology, Hannover Medical School, D-30625 Hannover, Germany

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

To analyze the function of each subunit of the receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF), GMR, we previously generated a single-chain chimeric receptor by fusion of the extracellular and transmembrane domain from the alpha -subunit (alpha -GMR) to the intracellular part of the beta -subunit (beta -GMR) introducing an additional glutamate residue at the fusion site (alpha /beta -GMR). We demonstrated the capacity of alpha /beta -GMR to bind GM-CSF with low affinity and to induce GM-CSF-dependent activation of tyrosine kinase activity and proliferation in transfected Ba/F3 cells. To further compare the functions of wild type and chimeric receptors, we now report that this alpha /beta -GMR is sufficient to mediate morphological changes, expression of alpha 4- and beta 1-integrin receptor subunits, and serine-phosphorylation of Akt kinase. To analyze the function of the glutamate residue at the fusion region of alpha /beta -GMR various point mutants changing this amino acid and its position were expressed in Ba/F3 cells. None of these mutants was capable of supporting GM-CSF-dependent proliferation; however, when beta -GMR was coexpressed, GM-CSF mediated short and long term proliferation. Interestingly, some mutants but not alpha /beta -GMR can induce proliferation in the presence of an anti-alpha -GMR antibody. These data demonstrate the significance of a glutamate residue in the transmembrane region of alpha /beta -GMR for ligand-induced receptor activation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Granulocyte-macrophage colony-stimulating factor (GM-CSF)1 mediates proliferation, survival, differentiation, and functional activities in myeloid cells (1, 2). GM-CSF binds to the GM-CSF receptor (GMR), consisting of a low affinity binding alpha -subunit (alpha -GMR) und a high affinity converting beta -subunit essential for signal transduction and shared with the receptors for IL-3 and IL-5 (common beta ; beta c; beta -GMR) (3-6). Both receptor chains belong to the cytokine receptor family characterized by common sequence and structural motifs such as the WSXWS motif in the extracellular domain close to the cell membrane (7).

The initial events of ligand-induced cytokine receptor activation are not completely understood. For single chain receptors such as EpoR or granulocyte colony-stimulating factor receptor, ligand-induced receptor dimerization is believed to mediate activation of receptor associated tyrosine kinases of the JAK family (8, 9). However, recent studies on the EpoR demonstrate a ligand-induced conformational change in preformed receptor complexes and suggest that dimerization or oligomerization may be necessary but not sufficient for the initiation of intracellular signal transduction (10). Both models for receptor activation, ligand-induced assembly of receptor chains and ligand-dependent conformational changes in preformed receptor complexes, may also be involved in the activation of heteromeric cytokine receptors such as GMR. Indeed, we have shown the GM-CSF-dependent coimmunoprecipitation of human alpha -GMR and beta -GMR in transfected NIH3T3 cells (11), and Woodcock et al. (12) demonstrated the existence of both preformed and GM-CSF-inducible GMR complexes with different ratios of each in different hematopoietic cells.

The initial event in intracellular signaling of cytokine receptors is believed to be the transphosphorylation and activation of members of the JAK tyrosine kinase family. The kinases may constitutively associate with receptor chains as demonstrated for the interaction of JAK2 and beta -GMR (13) or EpoR (14), and the kinases may be brought into a steric conformation enabling activation upon ligand-receptor interaction (10). Alternatively, JAKs may be recruited into ligand-activated receptor complexes (15), for example by ligand-induced unfolding of motifs in receptor subunits involved in receptor-kinase interaction. To analyze the contribution of individual receptor domains of human alpha -GMR and beta -GMR, we previously cloned a chimeric alpha /beta -GMR by fusion of the extracellular and transmembrane sequence of alpha -GMR to the intracellular part of beta -GMR that we found capable of GM-CSF binding with low affinity, receptor internalization, induction of tyrosine kinase activity, and short and long term proliferation of transfected Ba/F3 cells in the absence of wild type human alpha -GMR and beta -GMR (11). This alpha /beta -GMR contains an additional glutamate residue at the fusion region introduced for cloning purposes. In contrast to this construct, several groups reported on slightly different chimeric alpha /beta -GMR and IL-5Ralpha /beta -GMR constructs that were only functional as high affinity receptors in the presence of beta -GMR (16, 17). It was concluded from these studies that the cytoplasmic domain of alpha -GMR, although indispensable for the function of the wild type GMR (18-20), does not harbor nonredundant and necessary sequences for the functions analyzed so far in transfected cells. However, some unique signaling capacities of alpha -GMR have been reported (21, 22), and ligand-dependent signaling even in the absence of beta -GMR such as induction of glucose uptake has also been linked to alpha -GMR (23).

To further compare the functions mediated by the wild type GMR and the chimeric alpha /beta -GMR and to identify potential defects due to the lack of alpha -GMR sequences, we now extend the characterization of alpha /beta -GMR and demonstrate its capacity to signal for reorganization of the cellular cytoskeleton and morphological changes, for surface expression of alpha 4- and beta 1-integrins, and for serine phosphorylation of Akt protein kinase at Ser-473 in a GM-CSF-dependent manner. Moreover, we demonstrate the essential function of a glutamate residue at a specific position at the transition of the transmembrane to the cytoplasmic region for ligand-induced receptor function, providing new insights into initial events of GMR activation.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Reagents-- Restriction enzymes, DNA-modifying enzymes, and DNA molecular weight markers were purchased from MBI Fermentas (Vilnius, Lithuania) or New England Biolabs (Schwalbach, Germany). All PCR primers were synthesized by MWG-BIOTECH (Ebersberg, Germany). Fine chemicals were purchased from Sigma (Deisenhofen, Germany) and were of analytical or molecular biology grade. Agarose for gel electrophoresis was from Life Technologies, Inc.

Plasmids and Cloning of Human alpha /beta -GMR Mutants-- Cloning of the chimeric receptor alpha /beta -GMR introducing a glutamate residue has been described (11). Nucleotide positions of the beta -GMR cDNA insert are given according to Hayashida et al. (3). Site-directed mutagenesis was performed using the QuickChange Mutagenesis Kit (Stratagene) and oligonucleotides encoding the desired mutant sequences as recommended by the manufacturer (see Table II). Successful cloning was confirmed by restriction analysis and by sequencing of the mutated region. All constructs are cloned into pcDNA3 (InVitrogen).

Transfection of Ba/F3 Cells-- The murine cell line Ba/F3 was cultured in RPMI medium supplemented with glutamic acid, antibiotics, 5% fetal calf serum (Biochrome), and 10% WEHI-conditioned medium for the supply of murine IL (mIL)-3. In initial experiments, recombinant mIL-3 (10 ng/ml; Sigma) was found to be as effective as 10% WEHI-CM to induce proliferation, morphological changes, and Akt phosphorylation. For transfection, 1-2 × 106 cells were washed twice in RPMI 1640 without any supplements and electroporated at 350 V and 950 microfarads in 800 µl of serum-free medium in the presence of 20 µg of expression vector encoding the respective GMR constructs, purified by phenol/chloroform extraction. After 2 days, the cells were washed, split in half, and selected under two conditions in order to test the capacity of the transfected receptor variant to support GM-CSF-dependent proliferation: 1) in the presence of 20 ng/ml recombinant hGM-CSF but without mIL-3 or 2) in the presence of mIL-3 and the antibiotic G418 (Sigma) at a concentration of 1 mg/ml.

RT-PCR Analysis-- For analysis of mRNA expression of alpha /beta -GMR variants, total cellular RNA was prepared from transfected cells using TRIZOLTM reagent (Life Technologies) according to the instructions of the manufacturer. cDNA was transcribed from 2.5 µg of total cellular RNA in a 50-µl reaction mix containing 100 units of Moloney murine leukemia virus reverse transcriptase (RT) in the appropriate buffer conditions (Stratagene), 40 units of RNase inhibitor (RNase Block, Stratagene), 1 µg of oligo(dT) (Amersham Pharmacia Biotech), 10 mM dithiothreitol, and nucleotides at a concentration of 1 mM each (Roche Molecular Biochemicals). Using the primers 5'-GGAGGACAGGACCAAAAGG (sense) and 5'-CCCCAGGCTTGTTGACC (antisense), a beta -GMR fragment corresponding to nucleotides 2078-2711 was amplified from 10 µl of the RT reaction in a volume of 50 µl containing 50 pmol of both sense and antisense primer, 4 µl of 10× PCR buffer, including 15 mM MgCl2, and 2.5 units of Taq polymerase (Sigma) by 40 cycles of denaturation (95 °C), annealing (55 °C), and extension (73 °C). As a control, tubulin was amplified under the same conditions using the primers 5'-TTCCCTGCCCAGCT(G/C)AANGCNGACCTNCGCAAG (sense) and 5'-CATGCCCTCGCCNGTGTACCAGTGNANGAAGGC (antisense) (where N represents any nucleotide).

FACS Analysis-- Surface expression of the alpha /beta -GMR variants was analyzed using an antibody against an extracellular epitope of the human alpha -GMR subunit (Santa Cruz Biotechnology, Inc., Santa Cruz, CA; GM-CSRalpha S-20; 2 µg/106 cells). The cells were stained with a fluorescein isothiocyanate-labeled rabbit anti-mouse antibody (Dianova). For analysis of integrin expression, specific antibodies and isotype controls were obtained from Pharmingen (integrin alpha 4/mouse CD49d, 01270D; isotype control, 34491A; integrin beta 1/mouse CD29, 09351D; isotype control, 34481A). The cells were stained with an R-phycoerythrin-conjugated F(ab')2 goat anti-rat IgG Fragment (1623/112-116-143; Dianova). All antibodies were used at 10 µg/ml in phosphate-buffered saline.

Immunoblotting-- Transfected Ba/F3 cells were starved overnight for mIL-3 and hGM-CSF, respectively, and restimulated with either hGM-CSF or mIL-3 for 5 min. Cellular lysates were prepared as described (11). Briefly, stimulation was stopped by the addition of ice cold phosphate-buffered saline, the cells were collected by centrifugation at 500 g, and the pellets were suspended in lysis buffer. After 15-25 min on ice, the lysates were cleared by centrifugation at 4 °C, 12,000 × g for 15 min, and the supernatants were stored in aliquots at -80 °C or in Laemmli buffer at -20 °C. The protein concentrations were quantitated using Bio-Rad reagents, and equal amounts of cellular proteins were separated by SDS-polyacrylamide gel electrophoresis. Akt phosphorylation was analyzed by immunoblotting with an antibody recognizing Akt phosphorylated at Ser-473 (PhosphoPlus® Akt(Ser473) Antibody Kit, New England Biolabs). As a loading control, the same lysates were processed simultaneously and probed with a phosphorylation-independent anti-Akt antibody supplied with the kit.

Binding of 125I-Labeled GM-CSF-- Transfected Ba/F3 cells were studied for GM-CSF binding as described (11). Briefly, 7.5 × 105 cells were incubated for 60 min on ice with 125I-labeled GM-CSF (NEN Life Science Products) at different concentrations between 0.04 and 6.42 nM in the presence or absence of unlabeled GM-CSF (1 µM). However, in repeated experiments, saturation could not be reached under the conditions tested even if undiluted 125I-GM-CSF was added to the cell samples. After incubation, the samples were centrifuged, resuspended, and layered over a cushion of 0.7 ml of fetal calf serum. After centrifugation, the supernatant was discarded, and the radioactivity was measured in a Berthold MAG 315 gamma -counter. Untransformed specific binding data were analyzed by Scatchard plot assuming a single class of binding sites. KD and Bmax represent the equilibrium dissociation constant and the density of the binding sites per cell, respectively.

Proliferation Assay-- GM-CSF-dependent proliferation of Ba/F3 cells was assayed using the CyQUANT® Cell Proliferation Assay Kit (Molecular Probes, Inc., Eugene, OR) according to the instructions of the manufacturer. Briefly, the cells were seeded in 96-well tissue culture plates at a density of 105 cells per 200 µl in the absence or presence of hGM-CSF ranging from 1 pg/ml to 1 µg/ml. After 48-72 h, the cells were harvested by centrifugation, lysed in the buffer provided with the kit, and stained with the CyQUANT GR dye for 5 min at room temperature. Fluorescence was quantitated using an enzyme-linked immunosorbent assay reader (540 nm).

Prediction of Protein Structure-- Predictions of protein structure were done using the SEMAP program,2 utilizing the parameters of Chou and Fasman (24) and Kyte and Doolittle (25) to predict averaged secondary structure and hydrophobicity in protein chains, respectively. For the analysis discussed in this paper, a range of 4 amino acids was used for the averaged prediction.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

alpha /beta -GMR Mediates GM-CSF-dependent Changes in the Cell Morphology-- In order to compare the functional capacities of the wild type alpha  + beta  GMR and the chimeric alpha /beta -GMR and to identify potential defects due to the lack of alpha -GMR sequences in the chimeric receptor, we expressed alpha -GMR together with beta -GMR or alpha /beta -GMR alone in the murine IL-3-dependent cell line Ba/F3. This cell line expresses the murine IL-3 receptor including the murine common beta -chain but does not respond to murine GM-CSF, mIL-5, or hGM-CSF. Since human receptors for GM-CSF lack cross-reactivity to murine cytokines, their function can easily be analyzed after expression in these cells.

Growth factor-induced changes in cell morphology of Ba/F3 cells were studied by phase-contrast microscopy every 10 min after starvation and restimulation with mIL-3 and hGM-CSF, respectively. When untransfected, wild type alpha  + beta -GMR- or chimeric alpha /beta -GMR-expressing Ba/F3 cells were starved for growth factor overnight, all cells in culture were of a circular shape the next morning. However, 1 h after restimulation with mIL-3 or hGM-CSF for GMR-expressing cells, symmetric and asymmetric cylindric cells with motile protrusions and cells of unregular, biconcave shape were present, which increased in frequency to up to 50% within 6 h. In wild type alpha  + beta -GMR- and in chimeric alpha /beta -GMR-expressing cells, the effects of GM-CSF were more modest as compared with mIL-3 in some experiments. The mIL-3- or hGM-CSF-induced changes in cell morphology could be delayed by preincubation with the PI-3K inhibitor wortmannin and severely diminished or completely blocked by the repeated addition of wortmannin every 60 min without any loss of cell viability (Table I (top) and data not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Morphological changes of Ba/F3 cells in response to growth factor
Untransfected Ba/F3 cells (top) and transfected Ba/F3 cells (bottom) were starved overnight and restimulated the next morning with either 10% WEHI supernatant as a source of murine IL-3 (mIL-3) or with hGM-CSF (GM; 20 ng/ml). Wortmannin (Wo; 20 nM final concentration) was given 45 min prior to growth factor stimulation and at the time of stimulation alone (single dose) or every hour (repeated treatment; rep.). Thereafter, each sample was evaluated by phase-contrast microscopy after 1, 2, 3, 4, and 5 h for the presence of cells with marked morphological alterations as indicated: o, 0%; (+), >0-5%; +, 5-10%; ++, 10-25%; +++, 25-40%; ++++, >40% of the cells deviating from round shape. One representative experiment is documented.

GM-CSF-dependent Up-regulation of alpha 4- and beta 1-Integrin Expression in alpha /beta -GMR-expressing Ba/F3 Cells-- In previous studies, the ability of Ba/F3 cells to adhere to fibronectin has been used to monitor functional activity of these cells (26). Since we noted adhesion of alpha /beta -GMR-expressing Ba/F3 cells to fibronectin, but not to collagen or gelatin, after stimulation with mIL-3 or hGM-CSF in a Ca2+-dependent manner in preliminary experiments, the surface expression of murine alpha 4- and beta 1-integrin subunits was studied by FACS analysis. When untransfected Ba/F3 cells were starved and restimulated with mIL-3, a slight but reproducible up-regulation of alpha 4- and beta 1-integrin subunits at the cell surface was first detectable after 1 h and increased further during a time course of 3-6 h (data not shown). Similarly, in alpha /beta -GMR-expressing Ba/F3 cells stimulated for 4 h with either mIL-3 or hGM-CSF, a small but reproducible up-regulation of alpha 4- and more distinct beta 1-integrin expression was detected in several independent clones of alpha /beta -GMR-transfected cells (Fig. 1). hGM-CSF induced up-regulation of integrin subunits to the same extent as mIL-3.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 1.   Surface expression of integrin subunits alpha 4 and beta 1 in Ba/F3 cells. Ba/F3 cells transfected with alpha /beta -GMR were starved overnight for growth factor and stimulated the next morning with mIL-3 or hGM-CSF (hGM) for 4 h. Surface expression of integrin subunits alpha 4 and beta 1 was detected by FACS analysis and is shown as absolute number of positive cells graphed versus fluorescence intensity. Increased surface expression after growth factor stimulation is shown in comparison with the unstimulated controls for two representative clones transfected with alpha /beta -GMR. Negative controls with the second step antibody alone and with isotype control antibodies were identical in any conditions (not shown).

IL-3- and GM-CSF-induced Serine Phosphorylation of Akt Protein Kinase-- The phosphorylation of the serine/threonine kinase Akt at the regulatory position, Ser-473, was analyzed in untransfected, wild type alpha -GMR-, wild type alpha  + beta -GMR-, or chimeric alpha /beta -GMR-expressing Ba/F3 cells. Cells were starved overnight and restimulated the next morning with either mIL-3 or hGM-CSF. Akt phosphorylation was analyzed in cellular lysates by immunoblotting with a monoclonal antibody specific for Akt phosphorylated at Ser-473. Akt phosphorylated at Ser-473 is undetectable in untransfected Ba/F3 cells after overnight starvation but is clearly found after 5 min of stimulation with mIL-3 (Fig. 2A). As expected, untransfected cells do not respond to hGM-CSF. In contrast, both wild type alpha  + beta -GMR- and alpha /beta -GMR-transfected Ba/F3 cells display Akt phosphorylation at Ser-473 in response to both mIL-3 and hGM-CSF. The extent of Akt phosphorylation seems to be lower after stimulation with hGM-CSF as compared with mIL-3 in these experiments. When the cells were pretreated with wortmannin, the level of Akt phosphorylation was considerably lowered (Fig. 2B). Notably, in Ba/F3 transfectants expressing alpha -GMR alone, GM-CSF did not induce detectable phosphorylation of Akt at Ser-473.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 2.   Immunoblotting of Akt phosphorylated at Ser-473. Ba/F3 cells transfected with alpha /beta -GMR (shown as alpha /beta -GMR-Glu), alpha -GMR alone, or alpha  + beta -GMR as well as the parental cell line were starved overnight for growth factor and stimulated the next morning with mIL-3 or hGM-CSF for 5 min. Total cellular lysates were prepared and analyzed after SDS-polyacrylamide gel electrophoresis and Western blotting with an antibody against the phosphorylated epitope including Ser-473 of Akt or against a phosphorylation-independent Akt epitope (A). Where indicated, the cells were pretreated with the PI-3K inhibitor wortmannin (Wo) 45 min prior to growth factor stimulation (20 nM in Me2SO; Me2SO alone had no effect) (B).

Cloning and Expression of alpha /beta -GMR Point Mutants-- In contrast to chimeric constructs composed of sequences from alpha -GMR and beta -GMR reported by others (16), alpha /beta -GMR is capable of GM-CSF-dependent signal transduction as a low affinity GMR in the absence of beta -GMR. We therefore analyzed the function of the additional glutamate residue introduced at the fusion region of the transmembrane alpha -GMR sequence to the cytoplasmic sequence of beta -GMR by generation of the following point mutations using site-directed mutagenesis (Table II): deletion of the additional glutamate residue (alpha /beta -GMR-Delta Glu); replacement with glutamine (alpha /beta -GMR-Gln) or glycine (alpha /beta -GMR-Gly), respectively; and positioning of the glutamate residue by 1 (alpha /beta -GMR-Glu(-1)) or 14 amino acids (alpha /beta -GMR-Glu(-14)) to the N terminus, respectively. alpha /beta -GMR-Glu(-14) was generated in analogy to a transforming beta -GMR mutant V449E (27). alpha /beta -GMR and all variants were transfected into Ba/F3 cells, and clones were selected either in hGM-CSF or with G418 in the presence of mIL-3. Whereas Ba/F3 cells transfected with the alpha /beta -GMR cDNA could be grown in the presence of hGM-CSF as reported earlier (11), only drug-resistant and mIL-3-dependent clones could be selected for all alpha /beta -GMR mutants (up to three independent experiments per mutant; data not shown). Expression of the receptor cDNA was confirmed on the mRNA level by RT-PCR, and surface expression was studied by FACS analysis (Fig. 3). While alpha /beta -GMR and alpha /beta -GMR-Delta Glu were expressed at comparable levels, surface expression of alpha /beta -GMR-Gln, alpha /beta -GMR-Gly, and alpha /beta -GMR-Glu(-14) was more modest. Surface expression of alpha /beta -GMR-Glu(-1) could not be detected by FACS analysis in eight independent RT-PCR positive clones. Nevertheless, the variant turned out to be functionally expressed as confirmed by cotransfection of wild type beta -GMR (see below). To analyze GM-CSF binding by alpha /beta -GMR mutants with comparable receptor expression as determined by FACS analysis, the equilibrium binding characteristics of the clones alpha /beta -GMR and of alpha /beta -GMR-Delta Glu were studied. The estimated values for KD were 1.5 and 1.2 nM, and the receptor numbers per cell were 4700 and 2000 for alpha /beta -GMR- and alpha /beta -GMR-Delta Glu-expressing cells, respectively, as derived from Scatchard plot analysis. We also performed iterative fitting by least square regression and obtained comparable values (data not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Sequence comparison of the transmembrane region from GMR subunits and related molecules
The table indicates the transmembrane domain sequences of the wild type (wt) GMR subunits and the chimeric single chain variants together with the neighboring amino acids. The sequence from alpha GMR is in roman type, beta GMR is in italic type, and the fusion between alpha GMR and beta GMR sequence is marked by an asterisks. The putative transmembrane region is underlined according to published data (see references in the table). Amino acids inserted into the wild type sequence are given in parenthesis (boldface type), and amino acid exchanges are indicated by an arrow (boldface type).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Surface expression of alpha /beta -GMR variants expressed in Ba/F3 cells. Stable transfectants generated with the alpha /beta -GMR point mutants described in Table II were stained for surface expression of the receptor with an antibody against the extracellular part of human alpha -GMR in comparison with untransfected Ba/F3 cells. The absolute numbers of positive cells are graphed versus fluorescence intensity.

Function of alpha /beta -GMR Point Mutants-- For functional analysis, two independently derived Ba/F3 clones expressing each of the alpha /beta -GMR mutants were tested for GM-CSF-dependent proliferation in the absence of mIL-3. Except for alpha /beta -GMR transfectants, Ba/F3 cells expressing any of the alpha /beta -GMR mutants failed to proliferate in the absence of mIL-3, and all cells died within 48-72 h in the presence of hGM-CSF. However, when Ba/F3 clones expressing mutant alpha /beta -GMR constructs were co-transfected with wild type beta -GMR and selected with hGM-CSF, double transfectants were obtained for every alpha /beta -GMR mutant. Again, GM-CSF-dependent proliferation was assayed for double transfected cells. In contrast to the single transfectants, all double-transfected Ba/F3 cells were capable of signaling for GM-CSF-dependent proliferation (Fig. 4, A-F), whereas Ba/F3 cells transfected with beta -GMR alone did not grow in the presence of hGM-CSF (data not shown). In addition, all double transfected clones besides alpha /beta -GMR-Glu(-1)-expressing cells could be grown in hGM-CSF for several weeks in a factor-dependent manner. In contrast, alpha /beta -GMR-Glu(-1)-expressing cells tended to transform rapidly to factor-independent growth either in the presence or absence of beta -GMR after culture in mIL-3 or hGM-CSF in some experiments (data not shown).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 4.   GM-CSF dependent proliferation of transfected Ba/F3 cells. Ba/F3 cells stably transfected with alpha /beta -GMR or the point mutants described in Table II alone (black-diamond ) or with beta -GMR (black-square) were tested for GM-CSF-dependent proliferation in comparison with untransfected Ba/F3 cells (black-triangle). The cells were washed twice in the absence of growth factor and seeded in the presence of increasing GM-CSF concentrations in a 96-well cell culture plate. After 48-72 h, the cells were collected, and DNA was quantitated with CyQUANT dye GR. The data presented in this figure were generated in three different experiments. In all cases, the background-corrected maximum fluorescence intensity (100%) was between 63 and 139 relative fluorescence units at 540 nm.

To address the effect of bridging the single chain chimeric alpha /beta -GMR mutants, alpha /beta -GMR- and alpha /beta -GMR-Delta Glu-transfected Ba/F3 cells were seeded without growth factor in the presence of increasing concentrations of an anti-alpha -GMR antibody (Fig. 5). Interestingly, cross-linking of alpha /beta -GMR-Delta Glu but not alpha /beta -GMR by an anti-alpha -GMR antibody was sufficient to induce cell survival and proliferation in a dose-dependent manner. Similarly, alpha /beta -GMR-Gln-transfected Ba/F3 cells were also able to grow in the presence of anti-alpha -GMR antibody (data not shown).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Proliferation of transfected Ba/F3 cells in the presence of a cross-linking anti-alpha -GMR antibody. Ba/F3 cells expressing alpha /beta -GMR (A) or alpha /beta -GMR-Delta Glu (B) were washed twice in the absence of growth factor, and 5 × 104 cells were seeded either without growth factor (control) or in the presence of 20 ng/ml hGM-CSF, increasing amounts of anti-human alpha -GMR antibody (S-20; Santa Cruz Biotechnology), 10 ng/ml mIL-3, or 20 µg/ml anti-human beta -GMR antibody (S-16; Santa Cruz Biotechnology), respectively. Viable cells were counted after 4 days of culture. Untransfected Ba/F3 cells did not survive with either anti-alpha -GMR or anti-beta -GMR antibody in the absence of mIL-3 (not shown).

Prediction of Secondary Protein Structure-- To further analyze the role of the glutamate residue close to the transition of the transmembrane to the cytoplasmic region, we performed prediction of the hydrophobicity and of the secondary structure of this region for alpha /beta -GMR and each of the alpha /beta -GMR mutants in comparison with the wild type subunits (Fig. 6 and data not shown). Introduction of either glutamate (alpha /beta -GMR) or glutamine (alpha /beta -GMR-Gln) markedly changes the hydrophobicity as compared with alpha /beta -GMR-Delta Glu (Fig. 6). As expected, the effect of glycine introduction is more modest, while introduction of glutamate at positions -1 and -14 again enhance the hydrophilicity at the respective sites (not shown). Interestingly, the analysis suggests a beta -sheet rather than alpha -helical conformation of this part of the transmembrane domain for both wild type alpha - and beta -GMR as well as the chimeric variants.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 6.   Protein structure prediction for the transmembrane region of GMR molecules. SEMAP analysis of the transmembrane domain sequences, together with the neighboring amino acids indicated in Table II, was carried out for alpha /beta -GMR, alpha /beta -GMR-Delta Glu (shown as alpha /beta -GMR-Delta E), and alpha /beta -GMR-Gln. Amino acids are indicated corresponding to Table II. Hydrophilicity is plotted against amino acid positions. alpha  and beta  denote the probability that the respective amino acid supports alpha -helical or beta -sheet secondary structures, respectively, in the specific context. -, no predisposition.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

This study explores the functional capacities of a low affinity single chain chimeric alpha /beta -GMR in the absence of intracellular alpha -GMR sequences when stably expressed in Ba/F3 cells. We have previously shown that the chimeric alpha /beta -GMR is sufficient for GM-CSF-dependent short and long term proliferation of Ba/F3 and 32D cells (Ref. 11 and data not shown) and of inducing GM-CSF-dependent tyrosine phosphorylation of cellular substrates. We show here that alpha /beta -GMR-expressing Ba/F3 cells also display GM-CSF-dependent changes in cell morphology, surface expression of integrin subunits, and serine phosphorylation of the serine/threonine kinase Akt (or protein kinase B), implicated in antiapoptotic signaling (28, 29).

Cytoskeletal function and integrin expression are regulated by IL-3 or GM-CSF in wild type GMR and in alpha /beta -GMR-expressing Ba/F3 cells. Both functions are involved in regulating the interaction of hematopoietic cells with the microenvironment, and defects of both cytoskeletal functions and adhesion are found in Bcr-Abl-expressing cells (30, 31). The biochemical events mediating the effects of IL-3 or GM-CSF on cell morphology and alpha 4- and beta 1-integrin expression are currently not exactly characterized, but they are likely to involve small GTPases of the Rac/Rho/Cdc42 family for mediating membrane ruffling, formation of actin stress fibers, lamellipodia, and increased cell motility (32). We show here that IL-3- and GM-CSF-induced changes in cell morphology of Ba/F3 cells require activity of PI-3K and do not necessarily require sequences encoded by the cytoplasmic region of alpha -GMR.

The serine/threonine kinase Akt is linked to the apoptotic cell machinery through at least one of its substrates, the proapoptotic BCL-2 family member BAD, which can be phosphorylated at Ser-136 by Akt (29). BAD interacts with 14-3-3 protein isoforms in a phopsphoserine-dependent manner that appears to prevent the proapoptotic association of BAD with BCL-2 or BCL-XL (29). In addition, Akt has been shown to become phosphorylated and activated by IL-3 in hematopoietic cells (33). Both IL-3-induced phosphorylation and activation of Akt depend on PI-3K activity, and the pleckstrin homology domain of Akt is believed to mediate recruitment of Akt to the cell membrane by interaction with phosphatidylinositol products resulting from PI-3K activity. Although Akt has been demonstrated to be necessary and sufficient for suppression of apoptotic death of neuronal cells in culture (29, 34), its function on cytokine-dependent survival of hematopoietic cells is currently not known. We show here that both IL-3 and GM-CSF induce phosphorylation of Akt at Ser-473 in a PI-3K-dependent manner. In addition, whereas the cytoplasmic domain of alpha -GMR is not required, the cytoplasmic domain of beta -GMR is essential for serine phosphorylation of Akt. Interestingly, Ba/F3 cells expressing wild type alpha -GMR do not show detectable phosphorylation of Akt after stimulation with GM-CSF but can be grown with high concentrations of GM-CSF for several weeks. These data suggest that phosphorylation of Akt may not be essential for survival of hematopoietic cells under the conditions tested.

GM-CSF-dependent effects on cell morphology, integrin surface expression, and Akt phosphorylation in alpha /beta -GMR-transfected Ba/F3 cells occur in the absence of cytoplasmic alpha -GMR sequences. Therefore, with respect to all of these functions and in addition to survival, proliferation, receptor internalization, and tyrosine phosphorylation (11), the intracellular alpha -chain can be replaced by sequences of beta -GMR in this specific alpha /beta -GMR. Interestingly, human beta -GMR has been described to exist as a constitutively preformed homodimer both in vivo (35) and in vitro.3 Since the intracellular domain of alpha -GMR cannot be deleted in the wild type GMR without loss of receptor function (18-20), our data suggest a potential role of intracellular alpha -GMR sequences in the initial positioning or in inducing an appropriate conformational change of beta -GMR chains leading to activation of JAK2 through the wild type GMR. Additionally, sequences from alpha -GMR may also be involved in terminating GMR signaling.

Point mutations in the transmembrane region of alpha /beta -GMR were found to affect surface expression, GM-CSF binding, and functions such as mitogenic signaling, cytoskeletal changes, and phosphorylation of Akt in Ba/F3 cells expressing the respective GMR chimeras. Whereas deletion of the glutamate residue slightly enhances surface expression as compared with alpha /beta -GMR, replacement by glycine or glutamine at identical positions as well as positioning of the glutamate residue 14 amino acids to the N terminus decreases expression of the respective receptor. Interestingly, surface expression of alpha /beta -GMR-Glu(-1) was not detectable at all by FACS analysis, but GM-CSF-dependent signaling upon coexpression of beta -GMR implies its presence at the cell surface. We are currently investigating the mechanism of the reduced surface expression of the alpha /beta -GMR-Glu(-1) variant in comparison with the other receptor chimeras.

The mechanism involved in activation of the single chain alpha /beta -GMR, i.e. GM-CSF-induced homo-oligomerization or association with endogenous signaling molecules such as AIC2B or molecules that substitute for the function of alpha -GMR sequences, are currently not known. To distinguish between these possibilities, we transfected murine 3T3 fibroblasts with the cDNA encoding alpha /beta -GMR. So far we could not find any biochemical evidence for GM-CSF-dependent receptor function in several independent RT-PCR positive clones. However, since we failed to prove surface expression of alpha /beta -GMR so far, we cannot decide between both mechanisms of receptor activation in the fibroblast model (data not shown). In addition, receptor cross-linking by an anti-alpha -GMR antibody had no proliferative effect in alpha /beta -GMR transfected Ba/F3 cells. In contrast, alpha /beta -GMR-Delta Glu- and alpha /beta -GMR-Gln-transfected Ba/F3 cells, which cannot proliferate in response to hGM-CSF, were able to survive and proliferate in the presence of the tested anti-alpha -GMR antibody in a dose-dependent manner. Therefore, the glutamate residue in the single chain chimeric alpha /beta -GMR is essential for ligand-dependent receptor function but precludes activation by the cross-linking antibody used in this study. Since the reverse is true for the variants alpha /beta -GMR-Delta Glu and alpha /beta -GMR-Gln, ligand- and antibody-dependent receptor activation seem to be mutually exclusive.

As shown by the present study, a glutamate residue at a unique position in the transmembrane region at the transition to the cytoplasm is necessary for GM-CSF-dependent signaling of alpha /beta -GMR. Prediction of secondary protein structure cannot explain the unique features of the glutamate residue, since there was no significant difference between the functional alpha /beta -GMR and the nonfunctional alpha /beta -GMR-Gln. These data suggest that the negative charge introduced by the glutamate residue in alpha /beta -GMR as opposed to glutamine is essential for ligand-dependent receptor function of alpha /beta -GMR. Interestingly, there are several observations describing a specific role of glutamate residues within the transmembrane region for constitutive receptor activation. First, mutational screens for activating mutations in beta -GMR revealed, among others, an amino acid exchange V449E within the transmembrane domain, whereas V449Q does not activate beta -GMR (27). Second, the oncogenic activity of the neu/erb gene product relies on a V664E substitution localized within the transmembrane domain (36, 37). There is experimental evidence for this mutation to enhance constitutive oligomerization of oncogenic neu-V664E in contrast to c-neu (38, 39). When a panel of neu mutations was investigated, it turned out that besides V664E only V664Q and, to a much lower extent, V664D, had transforming capacity, in contrast to V663E or V665E and four other amino acid substitutions at position 664 (Gly, Lys, His, and Tyr) (36). However, when a mutation analogous to neu-V664E was introduced into the epidermal growth factor receptor, activity of the receptor remained fully ligand-dependent (40). In addition, charged amino acids in the transmembrane region are also believed to be essential for the interaction of natural killer cell inhibitory receptor with the immunoreceptor DAP12 (41).

Constitutive receptor oligomerization is believed to be necessary for constitutive receptor activation. For example, the transforming R129C mutation in the EpoR leads to constitutive receptor dimerization (42). However, the actual situation is more complex, since dimerization of EpoR may be necessary but not sufficient for receptor activation (10, 43). In contrast to constitutively active receptor mutants, the alpha /beta -GMR described remains fully ligand-dependent. Structural data of the transmembrane and the membrane-proximal region are needed to understand the molecular details of receptor interactions determining gain or loss of function of cellular receptors in a ligand-dependent or -independent manner.

    ACKNOWLEDGEMENTS

We acknowledge Claus Urbanke, Medical School Hannover, for carrying out predictions of secondary protein structure and assisting with their interpretation.

    FOOTNOTES

* This work was supported by Deutsche Forschungsgemeinschaft Grant Ed 34/2-2 (to M. E.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Medizinische Hochschule Hannover, Zentrum der Inneren Medizin, Abteilung Hämatologie und Onkologie, Carl-Neuberg Strasse 1, D-30623 Hannover, Germany. Tel.: 49-511-532-3020; Fax: 49-511-532-3611; E-mail: Eder.Matthias@MH-Hannover.de.

2 C. Urbanke, personal communication.

3 U. Kalina and M. Eder, unpublished data.

    ABBREVIATIONS

The abbreviations used are: GM-CSF, granulocyte-macrophage colony-stimulating factor; GMR, GM-CSF receptor; IL, interleukin; EpoR, erythropoietin receptor; PI-3K, phosphatidylinositol 3-kinase; hGM-CSF, human GM-CSF; mIL, murine IL; PCR, polymerase chain reaction; RT, reverse transcriptase; FACS, fluorescence-activated cell sorting. JAK, Janus kinase; CSRalpha , CS receptor alpha .

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Lopez, A. F., Williamson, D. J., Gamble, J. R., Begley, C. G., Harlan, J. M., Klebanoff, S. J., Waltersdorph, A., Wong, G., Clark, S. C., and Vadas, M. A. (1986) J. Clin. Invest. 78, 1220-1228
2. Metcalf, D. (1989) Nature 339, 27-30[CrossRef][Medline] [Order article via Infotrieve]
3. Hayashida, K., Kitamura, T., Gorman, D. M., Arai, K.-I., Yokota, T., and Miyajima, A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9655-9659[Abstract/Free Full Text]
4. Kitamura, T., Sato, N., Arai, K., and Miyajima, A. (1991) Cell 66, 1165-1174[CrossRef][Medline] [Order article via Infotrieve]
5. Tavernier, J., Devos, R., Cornelis, S., Tuypens, T., Van der Heyden, J., Fiers, W., and Plaetinck, G. (1991) Cell 66, 1175-1184[CrossRef][Medline] [Order article via Infotrieve]
6. Bagley, C. J., Woodcock, J. M., Stomski, F. C., and Lopez, A. F. (1997) Blood 89, 1471-1482[Free Full Text]
7. Bazan, J. F. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 6934-6938[Abstract/Free Full Text]
8. Schindler, C., and Darnell, J. E. (1995) Annu. Rev. Biochem. 64, 621-651[Medline] [Order article via Infotrieve]
9. Ihle, J. N. (1995) Nature 377, 591-594[CrossRef][Medline] [Order article via Infotrieve]
10. Livnah, O., Stura, E. A., Middleton, S. A., Johnson, D. L., Jolliffe, L. K., and Wilson, I. A. (1999) Science 283, 987-990[Abstract/Free Full Text]
11. Eder, M., Ernst, T. J., Ganser, A., Jubinsky, P. T., Inhorn, R., Hoelzer, D., and Griffin, J. D. (1994) J. Biol. Chem. 269, 30173-30180[Abstract/Free Full Text]
12. Woodcock, J. M., McClure, B. J., Stomski, F. C., Elliott, M. J., Bagley, C. J., and Lopez, A. F. (1997) Blood 90, 3005-3017[Abstract/Free Full Text]
13. Quelle, F. W., Sato, N., Witthuhn, B. A., Inhorn, R. C., Eder, M., Miyajima, A., Griffin, J. D., and Ihle, J. N. (1994) Mol. Cell. Biol. 14, 4335-4341[Abstract/Free Full Text]
14. Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Yi, T., Tang, B., Miura, O., and Ihle, J. N. (1993) Cell 74, 227-236[CrossRef][Medline] [Order article via Infotrieve]
15. Argetsinger, L. S., Campbell, G. S., Yang, X., Witthuhn, B. A., Silvennoinen, O., Ihle, J. N., and Carter-Su, C. (1993) Cell 74, 237-244[CrossRef][Medline] [Order article via Infotrieve]
16. Muto, A., Watanabe, S., Miyajima, A., Yokota, T., and Arai, K. (1995) Biophys. Biochem. Res. Commun. 208, 368-375
17. Takaki, S., Kanazawa, H., Shiiba, M., and Takatsu, K. (1994) Mol. Cell. Biol. 14, 7404-7413[Abstract/Free Full Text]
18. Weiss, M., Yokoyama, C., Shikama, Y., Naugle, C., Druker, B., and Sieff, C. A. (1993) Blood 82, 3298-3306[Abstract/Free Full Text]
19. Sakamaki, K., Miyajima, I., Kitamura, T., and Miyajima, A. (1992) EMBO J. 11, 3541-3549[Medline] [Order article via Infotrieve]
20. Ronco, L. V., Doyle, S. E., Raines, M., Park, L. S., and Gasson, J. C. (1995) J. Immunol. 154, 3444-3453[Abstract]
21. Doyle, S. E., and Gasson, J. C. (1998) Blood 92, 867-876[Abstract/Free Full Text]
22. Matsuguchi, T., Zhao, Y., Lilly, M. B., and Kraft, A. S. (1997) J. Biol. Chem. 272, 17450-17459[Abstract/Free Full Text]
23. Ding, D. X., Rivas, C. I., Heaney, M. L., Raines, M. A., Vera, J. C., and Golde, D. W. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2537-2541[Abstract/Free Full Text]
24. Chou, P. Y., and Fasman, G. D. (1974) Biochemistry 13, 211-222[CrossRef][Medline] [Order article via Infotrieve]
25. Kyte, J., and Doolittle, R. F. (1982) J. Mol. Biol. 157, 105-132[CrossRef][Medline] [Order article via Infotrieve]
26. Okuda, K., Smith, L., Griffin, J. D., and Foster, R. (1997) Blood 90, 4759-4766[Abstract/Free Full Text]
27. Jenkins, B. J., D'Andrea, A. D., and Gonda, T. J. (1995) EMBO J. 14, 4276-4287[Medline] [Order article via Infotrieve]
28. Hemmings, B. A. (1997) Science 275, 628-630[Free Full Text]
29. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. (1997) Cell 91, 231-241[CrossRef][Medline] [Order article via Infotrieve]
30. Salgia, R., Li, J. L., Ewaniuk, D. S., Pear, W., Pisick, E., Burky, S. A., Ernst, T., Sattler, M., Chen, L. B., and Griffin, J. D. (1997) J. Clin. Invest. 100, 46-57[Medline] [Order article via Infotrieve]
31. Bhatia, R., Wayner, E. A., McGlave, P. G., and Verfaillie, C. M. (1994) J. Clin. Invest. 94, 384-391
32. Nobes, C. D., and Hall, A. (1995) Cell 81, 53-62[CrossRef][Medline] [Order article via Infotrieve]
33. Songyang, Z., Baltimore, D., Cantley, L. C., Kaplan, D. R., and Franke, T. F. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11345-11350[Abstract/Free Full Text]
34. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. S., Kaplan, D. R., and Greenberg, M. E. (1997) Science 275, 661-665[Abstract/Free Full Text]
35. Muto, A., Watanabe, S., Miyajima, A., Yokota, T., and Arai, K. (1996) J. Exp. Med. 183, 1911-1916[Abstract/Free Full Text]
36. Bargmann, C. I., and Weinberg, R. A. (1988) EMBO J. 7, 2043-2052[Medline] [Order article via Infotrieve]
37. Bargmann, C. I., Hung, M. C., and Weinberg, R. A. (1986) Cell 45, 649-657[CrossRef][Medline] [Order article via Infotrieve]
38.